Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells.
Human immunodeficiency virus type 1 (HIV-1)-specific T-cell reactivity has been related to protection from disease progression. Optimal T-cell reactivity to HIV-1 presumably requires antigen processing and presentation by professional antigen-presenting cells, particularly dendritic cells (DC). Here we examined whether multiple HIV-1-specific T-cell functions are enhanced by stimulation with HIV-1 peptide-loaded DC derived from HIV-1-infected subjects on antiretroviral therapy. We first found that mature DC increased the number of gamma interferon (IFN-gamma)-producing T cells detected by enzyme-linked immunospot assay to overlapping 15-mer peptides of HIV-1 Gag and Nef, compared to stimulation with peptide-loaded, immature DC or to peptides without DC. IFN-gamma production was lower in response to large pools of the Gag and Nef peptides, regardless of presentation by DC. We further observed that HIV-1 peptide-loaded, mature DC stimulated greater CD8(+) and CD4(+) T-cell proliferation than did the peptides without DC and that T-cell proliferation was lower in response to larger pools of the peptides. The lower T-cell IFN-gamma and proliferation responses to the larger peptide pools were related to lower T-cell viability. Finally, the number of polyfunctional CD8(+) and CD4(+) T cells stimulated by HIV-1 peptide-loaded, mature DC, defined as positive by intracellular staining for more than one immune mediator (IFN-gamma, interleukin 2, tumor necrosis factor alpha, macrophage inhibitory protein 1beta, or CD107a), was greater than that stimulated by the peptides alone. These results indicate that DC can enhance multiple types of HIV-1-specific T-cell functions.
Huang
Xiao-Li
XL
Graduate School of Public Health and School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Fan
Zheng
Z
Borowski
Luann
L
Rinaldo
Charles R
CR
D000595:Amino Acid Sequence; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D015488:HIV Antigens / Q000235:genetics; D015658:HIV Infections / Q000276:immunology* / Q000473:pathology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D054311:nef Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology
D015488:HIV Antigens; D010446:Peptide Fragments; D054301:gag Gene Products, Human Immunodeficiency Virus; D054311:nef Gene Products, Human Immunodeficiency Virus; C514837:nef protein, Human immunodeficiency virus 1; D007371:Interferon-gamma
J Acquir Immune Defic Syndr. 2002 May 1;30(1):33-40
12048361
Immunity. 2007 Sep;27(3):406-16
17892849
J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7
17310936
AIDS. 2001 Sep 28;15(14):1749-56
11579235
J Virol Methods. 2007 Sep;144(1-2):115-21
17543395
J Immunol. 2004 May 1;172(9):5249-61
15100263
J Infect Dis. 2003 Jan 15;187(2):226-42
12552447
J Immunol. 2004 Nov 1;173(9):5372-80
15494483
Int Immunol. 2005 May;17(5):621-35
15824067
Nat Protoc. 2006;1(3):1507-16
17406442
Adv Pharmacol. 2008;56:75-92
18086409
Adv Immunol. 2007;95:111-48
17869612
J Immunol Methods. 2003 Dec;283(1-2):141-53
14659906
Cytometry. 2000 May 1;40(1):60-8
10754518
AIDS. 2006 Jan 9;20(2):171-80
16511409
J Intern Med. 2009 Jan;265(1):138-58
19093966
AIDS Res Hum Retroviruses. 2006 Mar;22(3):272-82
16545014
J Infect Dis. 2000 Apr;181(4):1249-63
10762561
Methods Mol Med. 2004;94:121-32
14959826
Vaccine. 2008 Jun 6;26(24):3002-7
18180082
AIDS Rev. 2004 Apr-Jun;6(2):79-88
15332430
Eur J Immunol. 2000 Jun;30(6):1676-82
10898504
Nat Rev Immunol. 2003 Aug;3(8):621-9
12974477
Trends Immunol. 2007 Nov;28(11):503-10
17950666
BMC Infect Dis. 2008 May 02;8:59
18454861
J Acquir Immune Defic Syndr. 2004 May 1;36(1):594-9
15097302
J Immunol Methods. 2003 Apr 1;275(1-2):19-29
12667667
Blood. 2009 Apr 23;113(17):3978-89
19109229
J Virol. 2005 Mar;79(5):3052-62
15709025
J Leukoc Biol. 2008 Jun;83(6):1530-40
18364435
AIDS Res Hum Retroviruses. 2002 Jun 10;18(9):611-8
12079556
Pediatr Res. 2007 Jun;61(6):692-7
17426646
Clin Vaccine Immunol. 2007 Sep;14(9):1127-37
17634507
Hum Immunol. 2004 May;65(5):523-36
15172453
J Virol. 2008 Apr;82(7):3391-404
18199637
J Immunol Methods. 2002 Feb 1;260(1-2):157-72
11792386
AIDS. 2004 Jul 23;18(11):1595-8
15238779
Front Biosci. 2007 Jan 01;12:2330-43
17127243
Nat Immunol. 2002 Nov;3(11):1061-8
12368910
Adv Immunol. 2002;80:1-70
12078479
J Virol. 2002 Jun;76(12):5925-36
12021325
J Immunol Methods. 2007 Sep 30;326(1-2):93-115
17707394
J Infect Dis. 2006 Dec 15;194(12):1650-60
17109336
Blood. 2006 Jun 15;107(12):4781-9
16467198
Annu Rev Immunol. 2000;18:767-811
10837075
PLoS One. 2007 Mar 28;2(3):e321
17389912
BMC Immunol. 2006 Apr 18;7:8
16620386
J Immunol. 1998 Nov 15;161(10):5284-95
9820501
Nat Med. 2008 Dec;14(12):1390-5
18997777
AIDS Res Hum Retroviruses. 2006 Nov;22(11):1081-90
17147493
J Exp Med. 2003 Dec 15;198(12):1909-22
14676302
J Immunol Methods. 2001 Sep 1;255(1-2):27-40
11470284
Int Immunol. 2006 Dec;18(12):1647-54
17035346
Clin Immunol. 2004 Mar;110(3):199-205
15047198